0.05). However, the natalizumab-treated group had a significantly lower birth weight than the control group (MD=-97.89; 95 percent CI=-171.32, -24.45), with 82.7% relapse rate (95 percent CI= 72.1-89.8), being highest in the second trimester (24.9%; 95% CI= 7.4, 58.0). Conclusion: While Natalizumab treatment appears to be relatively safe in terms of abortion rates, C-section rates, preterm delivery rates, and congenital anomalies, the increased relapse rate during pregnancy and lower birth weight observed necessitate careful monitoring and individualized care for pregnant MS patients taking natalizumab."/>
Review Article Online Publishing Date: | ||||||||||||
Natalizumab intake during pregnancy in women with multiple sclerosis: A meta-analysis of current evidence Abdulrahman Abdullah Al Malki, Alaa Saleh Albrakaty Alsharif, Khlood Fayez Aburaya, Sheema Iqbal Cheema, Ashwaq Khader Alharthi, Abeer Awadh Althobaiti.
|
How to Cite this Article |
Pubmed Style Malki AAA, Alsharif ASA, Aburaya KF, Cheema SI, Alharthi AK, Althobaiti AA. Natalizumab intake during pregnancy in women with multiple sclerosis: A meta-analysis of current evidence. IJMDC. Online First: 18 Mar, 2024. doi:10.24911/IJMDC.51-1708189353 Web Style Malki AAA, Alsharif ASA, Aburaya KF, Cheema SI, Alharthi AK, Althobaiti AA. Natalizumab intake during pregnancy in women with multiple sclerosis: A meta-analysis of current evidence. https://www.ijmdc.com/?mno=191273 [Access: March 26, 2024]. doi:10.24911/IJMDC.51-1708189353 AMA (American Medical Association) Style Malki AAA, Alsharif ASA, Aburaya KF, Cheema SI, Alharthi AK, Althobaiti AA. Natalizumab intake during pregnancy in women with multiple sclerosis: A meta-analysis of current evidence. IJMDC. Online First: 18 Mar, 2024. doi:10.24911/IJMDC.51-1708189353 Vancouver/ICMJE Style Malki AAA, Alsharif ASA, Aburaya KF, Cheema SI, Alharthi AK, Althobaiti AA. Natalizumab intake during pregnancy in women with multiple sclerosis: A meta-analysis of current evidence. IJMDC, [cited March 26, 2024]; Online First: 18 Mar, 2024. doi:10.24911/IJMDC.51-1708189353 Harvard Style Malki, A. A. A., Alsharif, . A. S. A., Aburaya, . K. F., Cheema, . S. I., Alharthi, . A. K. & Althobaiti, . A. A. (2024) Natalizumab intake during pregnancy in women with multiple sclerosis: A meta-analysis of current evidence. IJMDC, Online First: 18 Mar, 2024. doi:10.24911/IJMDC.51-1708189353 Turabian Style Malki, Abdulrahman Abdullah Al, Alaa Saleh Albrakaty Alsharif, Khlood Fayez Aburaya, Sheema Iqbal Cheema, Ashwaq Khader Alharthi, and Abeer Awadh Althobaiti. 2024. Natalizumab intake during pregnancy in women with multiple sclerosis: A meta-analysis of current evidence. International Journal of Medicine in Developing Countries, Online First: 18 Mar, 2024. doi:10.24911/IJMDC.51-1708189353 Chicago Style Malki, Abdulrahman Abdullah Al, Alaa Saleh Albrakaty Alsharif, Khlood Fayez Aburaya, Sheema Iqbal Cheema, Ashwaq Khader Alharthi, and Abeer Awadh Althobaiti. "Natalizumab intake during pregnancy in women with multiple sclerosis: A meta-analysis of current evidence." International Journal of Medicine in Developing Countries Online First: 18 Mar, 2024. doi:10.24911/IJMDC.51-1708189353 MLA (The Modern Language Association) Style Malki, Abdulrahman Abdullah Al, Alaa Saleh Albrakaty Alsharif, Khlood Fayez Aburaya, Sheema Iqbal Cheema, Ashwaq Khader Alharthi, and Abeer Awadh Althobaiti. "Natalizumab intake during pregnancy in women with multiple sclerosis: A meta-analysis of current evidence." International Journal of Medicine in Developing Countries Online First: 18 Mar, 2024. Web. 26 Mar 2024 doi:10.24911/IJMDC.51-1708189353 APA (American Psychological Association) Style Malki, A. A. A., Alsharif, . A. S. A., Aburaya, . K. F., Cheema, . S. I., Alharthi, . A. K. & Althobaiti, . A. A. (2024) Natalizumab intake during pregnancy in women with multiple sclerosis: A meta-analysis of current evidence. International Journal of Medicine in Developing Countries, Online First: 18 Mar, 2024. doi:10.24911/IJMDC.51-1708189353 |